SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cagiannos I,Karakiewicz P,Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003; 170: 17981803.
  • 2
    Thompson IM,Pauler DK,Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 22392246.
  • 3
    Albertsen PC,Hanley JA,Gleason DF,Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. [see comments] JAMA. 1998; 280: 975980.
  • 4
    Roach M,Lu J,Pilepich M, et al. Four prognostic groups predict long term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000; 47: 609615.
  • 5
    D'Amico AV,Whittington R,Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969974.
  • 6
    Zelefsky MJ,Lyass O,Fuks Z, et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 1998; 16: 33803385.
  • 7
    Kattan MW,Zelefsky MJ,Kupelian PA,Scardino PT,Fuks Z,Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000; 18: 33523359.
  • 8
    Roach M3rd,Weinberg V,McLaughlin PW,Grossfeld G,Sandler HM. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003; 61: 730735.
  • 9
    D'Amico AV,Chen MH,Roehl KA,Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004; 351: 125135.
  • 10
    D'Amico AV,Cote K,Loffredo M,Renshaw AA,Chen MH. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol. 2003; 169: 13201324.
  • 11
    Williams SG,Duchesne GM,Millar JL,Pratt GR. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 10821087.
  • 12
    Kwan W,Pickles T,Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 60: 10401046.
  • 13
    Weinberg V,Roach M,McLaughlin P,Sandler H. A new staging system for prostate cancer based on T-stage, Gleason score and PSA improves the prediction of survival. Paper presented at: Proceedings of the American Society for Therapeutic Radiology and Oncology, November 4–8, 2001; San Francisco, Calif.
  • 14
    American Society for Therapeutic Radiology and Oncology. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997; 37: 10351041.
  • 15
    Kaplan EL,Meier P. Non-parameteric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 16
    Cox DR. Regression models and life tables. J R Stat Soc. 1972; 34: 187202.
  • 17
    FlemingID, CooperJS, HensonDE, et al, eds. AJCC Cancer Staging Manual.5 ed. Philadelphia: Lippincott-Raven; 1998.
  • 18
    Crook J,Ludgate C,Malone S, et al. Report of a multicenter Canadian Phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 60: 1523.
  • 19
    Cooperberg MR,Lubeck DP,Mehta SS,Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 Pt 2): S21S25; discussion,S26–S27.
  • 20
    Kupelian PA,Potters L,Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 2533.
  • 21
    Lattanzi JP,Hanlon AL,Hanks GE. Early stage prostate cancer treated with radiation therapy: stratifying an intermediate risk group. Int J Radiat Oncol Biol Phys. 1997; 38: 569573.
  • 22
    Chism DB,Hanlon AL,Horwitz EM,Feigenberg SJ,Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59: 380385.
  • 23
    D'Amico AV,Keshaviah A,Manola J, et al. Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002; 53: 581587.
  • 24
    D'Amico AV,Renshaw AA,Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable inter-mediate-risk disease. J Clin Oncol. 2004; 22: 37263732.
  • 25
    Zietman AL,Chung CS,Coen JJ,Shipley WU. Ten-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol. 2004; 171: 210214.
  • 26
    Selek U,Lee A,Levy L,Kuban DA. Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2003; 57: 963967.
  • 27
    Lee LN,Stock RG,Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002; 52: 444452.
  • 28
    Potters L,Morgenstern C,Mullen EE,Fearn P,Jassal A,Kattan M. Twelve year outcomes following permanent brachytherapy in patients with clinically localized prostate cancer. Paper presented at: Proceeding of the American Society for Therapeutic Radiology and Oncology; October 3–7, 2004; Atlanta, Ga.
  • 29
    Zelefsky MJ,Leibel SA,Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. [see comments] Int J Radiat Oncol Biol Phys. 1998; 41: 491500.
  • 30
    Zelefsky MJ,Fuks Z,Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 11111116.
  • 31
    Sylvester JE,Blasko JC,Grimm PD,Meier R,Malmgren JA. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys. 2003; 57: 944952.
  • 32
    Kuban DA,Thames HD,Levy LB, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003; 57: 915928.
  • 33
    Williams SG,Millar JL,Dally MJ,Sia S,Miles W,Duchesne GM. What defines intermediate-risk prostate cancer? Variability in published prognostic models. Int J Radiat Oncol Biol Phys. 2004; 58: 1118.
  • 34
    Merrick GS,Butler WM,Galbreath RW,Lief JH,Adamovich E. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys. 2002; 52: 664673.
  • 35
    Michalski JM,Purdy JA,Winter K, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 1999; 46: 397402.
  • 36
    Speight JL,Weinberg VK,McLaughlin PW,Roach M,Sandler HM. 3D conformal radiotherapy improves PSA failure rates for intermediate risk patients at conventional doses. Paper presented at: Proceedings of the American Society for Therapeutic Radiology and Oncology; October 31-November 4, 1999; San Antonio, Tex.
  • 37
    Roach M3rd,Chen A,Song J,Diaz A,Presti JJr,Carroll P. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol. 2000; 18: 108114.
  • 38
    Lukka H,Warde P,Pickles T,Morton G,Brundage M,Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001; 8: 13141322.
  • 39
    D'Amico AV,Whittington R,Malkowicz SB, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 2000; 18: 11641172.
  • 40
    Kestin LL,Goldstein NS,Vicini FA,Martinez AA. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol. 2002; 168: 19941999.
  • 41
    Grossfeld GD,Latini DM,Lubeck DP, et al. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology. 2002; 59: 560565.